Coeptis Therapeutics Completes Transformational Merger with Z Squared, Pivots to Computing Infrastructure, and Rebrands as Z Squared Inc. with New Nasdaq Ticker ZSQR

summarizeSummary

Coeptis Therapeutics has completed its business combination with Z Squared Inc., rebranding as Z Squared Inc. and shifting its focus entirely to computing infrastructure, with shares commencing trading under the new ticker ZSQR on Nasdaq.

check_boxKey Events

• Business Combination Completed

  Coeptis Therapeutics Holdings, Inc. has completed its business combination with Z Squared Inc. on April 24, 2026, following SEC effectiveness of the Form S-4 and stockholder approval.

• Company Rebranded and Relisted

  The combined company has been renamed "Z Squared Inc." and its public shares are expected to commence trading on the Nasdaq Global Market under the ticker symbol "ZSQR" on Monday, April 27, 2026.

• Significant Ownership Shift

  Following the business combination, the company has approximately 51.5 million shares outstanding, with former Z Squared Opco Inc. stockholders owning approximately 85% and existing Coeptis stockholders owning approximately 15%.

• Pivot to Computing Infrastructure

  The company's business focus has entirely shifted from biopharmaceuticals to a vertically integrated computing infrastructure company, operating advanced computing equipment across North Carolina, South Carolina, and Iowa.

auto_awesomeAnalysis

This filing marks the completion of the previously announced transformational business combination between Coeptis Therapeutics and Z Squared Inc., fundamentally altering the company's identity and business model. Coeptis, which previously faced a going concern warning and engaged in dilutive financing, has now fully pivoted from biopharmaceuticals to a vertically integrated computing infrastructure company. The significant change in ownership, with former Z Squared Opco shareholders now holding 85% of the combined entity, represents a near-complete reset for the company and its strategic direction. Investors should re-evaluate the company based on its new business focus, management, and capital structure, as the original Coeptis business has been spun out.